Journal
CANCER RESEARCH
Volume 69, Issue 24, Pages 9376-9384Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-0400
Keywords
-
Categories
Funding
- Istituto Superiore Sanita-Alleanza contro il Cancro [ACC8]
- Italy-U.S. program [527/A/3A/1]
- Italian Association for Cancer Research
- Department of Defense [PC 040972, DAMD17-03-0370]
- NIH [RO1 CA108835, RO1 AI44129]
Ask authors/readers for more resources
The development of effective antitumor immune responses is normally constrained by low-avidity, tumor-specific CTLs that are unable to eradicate the tumor. Strategies to rescue antitumor activity of low-avidity in melanoma-specific CTLs in vivo may improve immunotherapy efficacy. To boost the in vivo effectiveness of low-avidity CTLs, we immunized mice hearing lung melanoma metastases with artificial antigen-presenting cells (aAPC), made by covalently coupling (MHC)-M-pep-Ig dimers and B7.1-Ig molecules to magnetic beads. aAPC treatment induced significant tumor reduction in a mouse telomerase antigen system, and complete tumor eradication in a mouse TRP-2 antigen system, when low-avidity CTLs specific for these antigens were adoptively transferred. In addition, in an in vivo treatment model of subcutaneous melanoma, aAPC injection also augmented the activity of adoptively transferred CTLs and significantly delayed tumor growth. In vivo tumor clearance due to aAPC administration correlated with in situ proliferation of the transferred CTL. In vitro studies showed that aAPC effectively stimulated cytokine release, enhanced CTL-mediated lysis, and TCR down-regulation in low-avidity CTLs. Therefore, in vivo aAPC administration represents a potentially novel approach to improve cancer immunotherapy. [Cancer Res 2009:69(24):9376-84]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available